Long-term results from the Phase 2 NICHE-2 trial reported a striking recurrence outcome in dMMR colon cancer using short-course neoadjuvant immunochemotherapy. Among 111 patients treated with four weeks of neoadjuvant nivolumab plus ipilimumab, none experienced disease recurrence, and all patients were alive at a median postoperative follow-up of 58.7 months. The regimen underscores a potential de-escalation strategy for a molecularly defined population, focusing on immune checkpoint therapy before surgery rather than extended postoperative treatment. For clinicians, it provides a high bar for how durable immune control can be after limited exposure. Stakeholders will watch for ongoing validation, including comparisons with other trial cohorts, the full safety dataset, and whether pathologic and biomarker correlates can help identify who benefits most within dMMR disease.